Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as G-Pump™ (glucagon infusion)
G-Pump · 1 trial · 2 indications
Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose \< 75 mg/dl) and notifies the investigator to initiate treatment. Reported as the number of successful identifications.
| Arm | Type | Description |
|---|---|---|
| G-Pump™ (glucagon infusion) | EXPERIMENTAL | 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump |
| Name | Type | Description |
|---|---|---|
| G-Pump™ (glucagon infusion) | DRUG | 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump |
Inclusion Criteria: * diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose. * willingness to provide inform...
G-Pump is an investigational glucagon infusion therapy developed by Xeris Biopharma Holdings, Inc. for hypoglycemia. It is delivered from an OmniPod pump and was studied in post-bariatric surgery patients to prevent low blood glucose. It is a small molecule product in Phase 2 development and is not approved for commercial use.
G-Pump is being developed to prevent hypoglycemia, with its clinical study focused on post-bariatric surgery patients who experience low blood sugar. The Phase 2 trial enrolled adults aged 18 and older of any sex in the United States. It remains investigational and has not been approved for any indication.
G-Pump is developed by Xeris Biopharma Holdings, Inc., which trades on the Nasdaq under the ticker XERS. The company is the sponsor behind the glucagon infusion program and its delivery from an OmniPod pump for hypoglycemia prevention in post-bariatric surgery patients.
G-Pump is in Phase 2 development. Its single recorded trial, NCT02733588, is a completed Phase 2 study. Because no approval has been granted, G-Pump remains an investigational therapy rather than an approved product, and further clinical development would be required before any regulatory submission.
G-Pump has been studied in one completed Phase 2 trial, NCT02733588, titled Delivery of G-Pump (Glucagon Infusion) From an OmniPod to Prevent Hypoglycemia in Post-Bariatric Surgery Patients. The uncontrolled, non-randomized study enrolled 8 participants in the United States and has completed; no active trials are ongoing.
Yes. G-Pump is also known as G-Pump (glucagon infusion), so searches for either name refer to the same Xeris Biopharma Holdings, Inc. product. It is a small molecule glucagon therapy delivered continuously from an OmniPod pump, studied in Phase 2 for preventing hypoglycemia in post-bariatric surgery patients.